Table 2. Clinical characteristics of the SOS/VOD positive and negative patients.
| Risk factors | SOS/VOD (+) | SOS/VOD (−) | p value |
|---|---|---|---|
| n = 7 | n = 20 | ||
| Transplant-related factors | |||
| Myeloablative conditioning (TBICy+BuCy) | 4 (57%) | 12 (60%) | 0.8946 |
| BuCy | 1 (14%) | 8 (40%) | 0.2142 |
| TBICy | 3 (43%) | 4 (20%) | 0.2349 |
| Unrelated donor | 7 (100%) | 15 (75%) | 0.1427 |
| Second HSCT | 1 (14%) | 6 (30%) | 0.4142 |
| Patient- and disease-related factors | |||
| Age > median 38 years | 3 (43%) | 11 (55%) | 0.5800 |
| Female gender | 2 (28%) | 11 (55%) | 0.2284 |
| AML | 4 (57%) | 16 (80%) | 0.2349 |
| Advanced disease (beyond second CR or relapse) | 2 (29%) | 3 (15%) | 0.4263 |
| Iron overload (ferritin > 1000 ng/ml) | 6 (75%) | 1 (5%) | 0.0247 |
| Previous liver disease | 1 (14%) | 1 (5%) | 0.4195 |
Abbreviations: BuCy - busulfan plus cyclophosphamide, TBI Cy - total body irradiation plus cyclophosphamide.
p value between SOS (+)/VOD and SOS/VOD (−) group > 0.05 – not significant.
p value < 0.05 – statistically significant.